SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000886163-22-000003
Filing Date
2022-01-14
Accepted
2022-01-14 16:23:37
Documents
12
Period of Report
2022-01-14
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K lgnd-20220114.htm   iXBRL 8-K 32240
  Complete submission text file 0000886163-22-000003.txt   167642

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20220114.xsd EX-101.SCH 1909
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20220114_lab.xml EX-101.LAB 24132
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20220114_pre.xml EX-101.PRE 12516
6 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20220114_htm.xml XML 10829
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 22532133
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences